After completing this module, you should be more aware of:

·       The wide range of recognised headache disorders;

·       The prevalence of major headache types and the associated health burden;

·       The symptoms of migraine and cluster headache and how they compare;

·       Some of the pathophysiology of migraine and cluster headaches;

·       Some of the neurotransmitters associated with migraine and cluster headache;

·       Why the neuropeptide calcitonin gene-related peptide (CGRP) has been the focus of drug development;

·       How targeting serotonin//5-HT receptors more selectively has led to the development of ditans as a potential successor to triptans;

·       The mains areas of drug development around CGRP – receptor blockers (gepants) and monoclonal antibodies;

·       The current status of CGRP medicines coming to the market.